By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Pharmaceuticals, Inc. 

900 Ridgebury Road

Ridgefield  Connecticut  06877  U.S.A.
Phone: 203-798-9988 Fax: n/a


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit and follow us on Twitter at

Value Through Innovation

Our vision of Value through Innovation (VTI) guides our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. It also helps us foster value creation throughout our company and to look to the future with constantly renewed commitment and ambition.

Our Lead & Learn principles outline ways in which we can build on our culture of working together to realize and deliver Value through Innovation. These principles encourage us to take risks, ask questions, and seize opportunities in an environment of shared leadership and learning.

Our Success Depends on our People

For more than 125 years, the commitment, innovative-thinking and creative power of our people has made Boehringer Ingelheim one of the fastest growing pharmaceutical companies and an employer of choice. Our workplace reflects our distinctive and innovative culture, built on a foundation of mutual respect and fairness.

We have high expectations and require employees at all levels of the organization to take initiative, stay connected, grow together and achieve outstanding results. To enable this high performance we provide opportunities for personal growth, a collaborative and inclusive work environment and exceptional employee benefits and we reward high achievement with recognition, opportunities and competitive pay.

Driven by a Different Philosophy

We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to create a healthy working environment, meaningful work, diversity, mobility, networking and work-life balance.

In a world where business is too often driven by short-term financial goals, Boehringer Ingelheim is truly a company with a different philosophy. As one of the fastest growing pharmaceutical companies in the world, our focus is on helping patients, serving our customers and improving the quality of life for the millions of people who rely on us. Simply put, we remain committed to doing the right thing – for our customers, our communities, our employees and everyone we serve.

Because our products enhance millions of lives, our employees experience the satisfaction of doing important work. Their achievements bring them recognition, and opportunities for career growth. We invite you to join us in improving lives worldwide.

Key Statistics

Ownership: Private

Web Site: Boehringer Ingelheim Pharmaceuticals, Inc.
Employees: More than 9,000 Employees in the US; 42,000 Worldwide

Company News
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Results from The INJOURNEY Trial Investigating Ofev With Add-On Pirfenidone Provide New Insights Into This Combination Treatment For IPF 9/11/2017 8:15:45 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Receives FDA Approval For Cyltezo (Adalimumab-Adbm), A Biosimilar To Humira, For The Treatment Of Multiple Chronic Inflammatory Diseases 8/29/2017 9:05:43 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Support Program Provides Free Medicine And Resources For People Living With COPD Prescribed STIOLTO RESPIMAT (Tiotropium Bromide And Olodaterol) Inhalation Spray 10/12/2016 9:47:52 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Of INPULSIS Trials Demonstrates Efficacy Of OFEV (Nintedanib) Across A Range Of IPF Patients Using Broader Diagnostic Criteria 6/27/2016 8:11:21 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: : Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) In Emergency Situations 4/4/2016 9:17:37 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Confirms OFEV (nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations 2/25/2016 6:33:53 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Country Music Artist Joe Nichols Raises Awareness of Rare Lung Disease That Claimed His Father's Life and Leaves Those Affected "Breathless" 2/18/2016 10:14:28 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range Of Measures 2/9/2016 6:17:36 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Published Data Show STIOLTO RESPIMAT Provides Clinically Meaningful Improvements In COPD Health-Related Quality Of Life Measure 8/18/2015 6:35:15 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: STIOLTO RESPIMAT Now Available In The United States For The Treatment Of COPD 6/30/2015 6:42:30 AM